Previous Up

Ligand-based Drug Design: Homework (Winter 2009)

Influenza is a serious viral disease that is often resistant to drug treatments. It is very likely that were the worldwide avian influenza (H5N1) pandemic take place, the virus will acquire resistance to the current first-line influenza drug oseltamivir (Tamiflu). Thus, it is necessary to develop analogs of oseltamivir that can fight resistant strains of the virus.

The three-dimensional structure of oseltamivir (in active carboxylate form) bound to its target (influenza neuraminidase) is known. This structure of the bioactive conformer bound to neuraminidase is available from PDB (ID code 2HT8). Visualization of the bound inhibitor shows that the cyclohexene ring adopts a conformation in which the alkyl ether side-chain is in the equatorial position.

CC(C)O[C@@H]1C=CCCC1

To pursue the fragment-based drug discovery effort, a small analog containing the cyclohexene ring and the isopropyl side-chain was created. This molecule, (S)3-isopropoxy-cyclohexene, is shown on the right. However, this fragment did not show a good binding to neuraminidase. Conformational analysis of this molecule was performed with the MM3 force field. It was found that isopropoxy side-chain in this fragment can exist in either equatorial or axial ring position. Thus, an hypothesis was proposed that the weak binding of the fragment could be due to the fragment adopting a different conformation than the bioactive conformation of known good binder oseltamivir.

With the help of literature searches and/or computer modeling, answer the following questions:


Previous Up

Tutorial by Dr. Kalju Kahn, Department of Chemistry and Biochemistry, UC Santa Barbara. ©2007-2011